Psilocybin therapy is not legal in California. Psilocybin remains a Schedule I controlled substance under both state and federal law, and no licensed therapeutic framework exists. Every major legislative effort to change that has either failed to pass or been vetoed, and the bills currently moving through Sacramento focus on narrow research programs rather than public access.
How California and Federal Law Classify Psilocybin
California lists psilocybin as a Schedule I hallucinogenic substance under Health and Safety Code Section 11054(d)(18).1California Legislative Information. California Code, Health and Safety Code HSC 11054 Schedule I is the most restrictive category the state uses, reserved for substances treated as having high abuse potential and no accepted medical use.
Federal law does the same. Under 21 U.S.C. § 812, psilocybin is a Schedule I controlled substance, officially deemed to have “no currently accepted medical use in treatment in the United States” and to lack “accepted safety for use…under medical supervision.”2Office of the Law Revision Counsel. 21 USC 812 Schedules of Controlled Substances That dual classification is the core of the problem. Even a future California therapy law would leave federal prohibition intact, producing the same state-versus-federal tension that has shadowed the state’s marijuana industry.
Criminal Exposure for Possession, Sale, and Offering “Therapy”
Simple possession of psilocybin falls under Health and Safety Code Section 11377. Since voters passed Proposition 47 in 2014, simple possession of most controlled substances is a misdemeanor punishable by up to one year in county jail.3Judicial Council of California. Proposition 47 Frequently Asked Questions People with prior convictions for serious violent felonies or sex offenses requiring registration can still be charged with a felony for the same conduct.
Proposition 36, which voters approved in November 2024, added a “treatment-mandated felony” track for repeat drug offenders, but the provision targets substances such as fentanyl, heroin, cocaine, and methamphetamine rather than psilocybin.4Legislative Analyst’s Office. Proposition 36
Distribution is a different story. Possession with intent to sell, sale, transportation, or furnishing psilocybin are felonies under Health and Safety Code Sections 11378 and 11379, with potential state prison sentences. A practitioner charging clients for guided psilocybin sessions is not practicing medicine in the eyes of the law. They are distributing a Schedule I substance.
Federal penalties for distribution are more severe. A first offense involving any amount of a Schedule I substance can bring up to 20 years in federal prison and fines up to $1 million for an individual. If death or serious injury results, the floor rises to 20 years with a possible life sentence. A second offense raises the ceiling to 30 years, with mandatory life imprisonment if someone dies.5U.S. Drug Enforcement Administration. Federal Trafficking Penalties Federal agents retain full authority to investigate and prosecute psilocybin offenses regardless of what California does.
What Local Deprioritization Actually Does
Oakland, Santa Cruz, Arcata, Berkeley, and San Francisco have passed resolutions telling local police to treat enforcement of laws against entheogenic plants, including psilocybin mushrooms, as the lowest priority. Oakland’s council voted unanimously in June 2019 that city funds would not be used to help enforce criminal penalties for personal use and possession. None of these resolutions authorize commercial sale or manufacturing.
These measures do not change state or federal law. Police can still arrest, prosecutors can still file charges, and federal agents are unaffected. Deprioritization is a signal, not a shield. Treating it as legal cover is a mistake that can end in criminal charges.
Why the Legislature Hasn’t Legalized Psilocybin Therapy
The legislative record shows a pattern of bills getting narrower, and still not clearing the bar.
SB 519 (2021–2022). Senator Scott Wiener’s first attempt would have made it lawful for adults 21 and older to possess, obtain, give away, or transport specified quantities of psilocybin, DMT, mescaline, LSD, MDMA, and ibogaine for personal use or “facilitated or supported use,” and would have convened a state working group to recommend regulations.6California Legislative Information. California Senate Bill 519 It did not pass.
SB 58 (2023–2024). Wiener’s narrower successor dropped LSD, MDMA, and ibogaine, keeping psilocybin, psilocyn, DMT, and mescaline. Both chambers passed it. Governor Newsom vetoed it on October 7, 2023, writing that “this bill would decriminalize possession prior to these guidelines going into place, and I cannot sign it.” His veto message asked the legislature to first build regulated treatment guidelines, including “dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments, and medical clearance of no underlying psychoses.”7Governor of California. Senate Bill 58 Veto Message That veto set the terms for everything after: framework first, then access.
SB 1012 (2024). Wiener responded with the Regulated Psychedelic Facilitators Act and the Regulated Psychedelic-Assisted Therapy Act, which would have created a licensing board, required regulations by January 1, 2026, and opened license applications by April 1, 2026, covering psilocybin, psilocyn, DMT, mescaline, and MDMA. Violations would generally be a misdemeanor punishable by up to six months in county jail, a fine up to $2,500, or both, along with potential license action. Sexual exploitation by a facilitator during treatment carried separate penalties, escalating for repeat offenses or multiple victims to state prison time of up to three years and fines up to $10,000.8California Legislative Information. SB 1012 The Regulated Psychedelic Facilitators Act SB 1012 did not advance out of the legislature.
The 2025–2026 Pivot to Research
After broad decriminalization and full therapy frameworks both failed, lawmakers shifted to a research-first strategy focused on veterans and first responders.
- AB 1103 was signed into law in October 2025. It streamlines state review of psychedelic-focused research studies by allowing qualifying applications to be approved by a smaller cohort of the Research Advisory Panel rather than requiring a full panel vote.
- SB 751, introduced by Senator Josh Becker with bipartisan co-sponsorship, would create a Veterans and Former First Responders Research Pilot Program and request the University of California to establish local pilot programs in up to five counties. Psilocybin would be administered under practitioners experienced in psychedelic therapy, and participants would need to be 21 or older and complete specified assessments.9Plural Policy. SB 751 California 2025-2026
- AB 2489 would allow the state’s Research Advisory Panel to submit FDA applications for clinical trials using Schedule I and II controlled substances, including psilocybin, for veterans.
None of these bills legalizes psilocybin therapy for the general public. They build a research track that could support broader access later.
Legal Ways to Access Psilocybin Therapy
For someone in California who wants a legal path today, the options are narrow.
Enroll in an FDA-approved clinical trial. Clinical trials operate under federal research authorizations that carve out a lawful use for participants and investigators. Eligibility depends on the specific study’s protocol and inclusion criteria.
Travel to Oregon. Oregon is the only state with an operational psilocybin therapy framework, created by Measure 109 in 2020. Psilocybin can only be administered at licensed service centers under the supervision of licensed facilitators. There are no retail sales and no take-home supply. Traveling home to California with psilocybin, of course, puts you back in the same criminal framework described above.
Wait for California law to change. Given the veto history and the current focus on research-only bills, a signed law authorizing general therapeutic access is not on the near horizon.
Why the Gray Market Is Risky for Everyone Involved
Underground practitioners offering psilocybin “therapy” are exposed to felony distribution charges under state law, federal trafficking charges, professional license revocation if they hold any healthcare credential, and civil liability if a client is harmed. Informed consent paperwork does not change the criminal analysis.
Clients carry risk too. Beyond the misdemeanor possession exposure, underground sessions come with no regulatory oversight of substance purity, no standardized dosing, no screening for contraindicated conditions such as psychotic disorders, and no legal recourse if something goes wrong. The safeguards Governor Newsom and legislators have been arguing about are the safeguards that do not exist yet. Until California passes a signed framework, or until the FDA approves a psilocybin-based medicine and the DEA reschedules it, psilocybin therapy in the state remains outside the law.